peroxiredoxin like 2AGenealiases: Adrx · C10orf58 · FAM213A · PAMM
Q-omics provides the consensus-scored PRXL2A profile across patient tissues and cancer cell-line models. PRXL2A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRXL2A is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, PRXL2A protein abundance shows 21,071 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where PRXL2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRXL2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRXL2A survival associations across molecular data types. PRXL2A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRXL2A RNA expression–survival associations across cancer types. High PRXL2A expression shows unfavorable associations in HNSC, ACC, LAML and BRCA, but favorable associations in KIRC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRXL2A RNA expression.
This table summarizes PRXL2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PRXL2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRXL2A shows lower tumor expression in KICH, COAD, KIRP and THCA and higher tumor expression in LUAD and HNSC. The KICH box plot shows higher PRXL2A RNA expression in normal versus tumor tissue (log2 FC = −2.609, t-test p < 0.001).
This table shows molecular features associated with PRXL2A in patient tissues and cancer cell lines. In patient samples, PRXL2A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRXL2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
